GeneDx Holdings Corp. (WGS) Earnings
GeneDx Holdings Corp. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $-0.19. WGS has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise +53.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $-0.06 | $-0.28 | -366.7% | $102M | -9.1% |
| Feb 23, 2026 | $0.11 | $0.14 | +27.3% | $121M | +5.1% |
| Jul 29, 2025 | $0.10 | $0.50 | +400.0% | $103M | +4.1% |
| Apr 30, 2025 | $0.11 | $0.28 | +154.5% | $87M | +2.1% |
| Feb 18, 2025 | $0.04 | $0.70 | +1650.0% | $96M | +21.1% |
| Feb 20, 2024 | $-0.60 | $-0.59 | +1.7% | $57M | +3.6% |
| Mar 14, 2023 | $-0.16 | $-0.25 | -56.3% | $61M | -13.5% |
| Nov 14, 2022 | $-0.21 | $-0.20 | +4.8% | $83M | +22.9% |
| Aug 15, 2022 | $-0.21 | $-0.25 | -19.0% | $36M | -46.5% |
| May 12, 2022 | $-0.31 | $-0.31 | +0.0% | $54M | +13.6% |
| Mar 14, 2022 | $-0.26 | $-0.17 | +34.6% | $58M | +16.4% |
| Nov 15, 2021 | $-0.19 | $-0.43 | -126.3% | $43M | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• GeneDx continued mission of enabling genomics-driven healthiest life, with exome and genome volume up 34% Y/Y. • Identified two factors for lower than expected total revenue: lower blended average reimbursement rate and softer non-core business line performance. • Fabric genomics acquisition integrated, focusing resources on international growth and key domestic drivers, lowering 2026 revenue expectations. • Biopharma and data business had positive momentum but fell short due to longer sales cycle, positioned as upside as it ramps. • Took $25 million OPEX cut, focusing on growing exome and genome utilization, optimizing unit economics, and delivering leading products. • Walked through customer segments: geneticists, pediatric specialists, NICU, General Pediatrics, prenatal, detailing growth and challenges in each.
Guidance
• Reduced full-year revenue guidance by 12%, expecting total revenue $475 to $490 million. • Exome and genome volume growth at least 30%, adjusted gross margin approximately 70%, aiming for adjusted profitability. • Q2 2026 expected total revenues $110 to $112 million, exome and genome volume ~30,000 tests, exome and genome revenue ~$100 million, adjusted net loss ~$5 million in Q2, moving to profitable in Q3.
Segment performance
In Q1, Exome and genome volume grew 34% year over year. Total revenue was $12 million lower than expected, driven by a lower blended average reimbursement rate for exome and genome (~$5.5M) and softer performance from non-core business lines (~$6.5M). Exome and genome revenue was $90.6 million in Q1. Geneticists are leaning into genome, pediatric specialists saw steady growth but lower exome ARR, NICU had good progress with rapid and ultra-rapid genomes, General Pediatrics is an early stage market with encouraging signals, and prenatal had building demand. Non-core business lines like Fabric and BioPharma had lower revenue contributions due to various factors.
Risks & headwinds
• Uncertainty in reimbursement dynamics for exome and genome, especially with genome having lower coverage and reimbursement rates. • Longer sales cycles in biopharma and data business impacting revenue. • Transitory nature of product mix shifts affecting blended average reimbursement rate, which needs careful management. • Execution challenges in new sales channels and markets, such as in General Pediatrics and prenatal.
Analyst Q&A
Q: On Q2 guidance and NICU traction.
A: Q2 guide from strong momentum, NICU has good traction with expanded sales force.
Q: Part of guidance from end markets and competitive dynamics.
A: In right channels, tweaking sales strategy for optimization.
Q: Commercial footprint and sales force productivity.
A: 4 sales teams, early stage for some, watching Salesforce productivity.
Q: Genome mix and pricing.
A: Aim for genome ASP to parity with exome, work on coverage and revenue cycle.
Q: $11M cut and volume guidance.
A: Extensive channel review, tighter assumptions.
Q: Pricing and reflex product.
A: Reflex as tool, genome margin good, exome higher.
Q: Linearity and competitive dynamics.
A: Volume came in ahead, no new competitive dynamics, working on long read.
Q: Non-core revenue and health.
A: Fabric refocused on international, biopharma with longer cycles.
Q: Genome-exome mix and market penetration.
A: Genome 40% outpatient volume, penetration based on diagnosis day.
Q: Genome mix stability and OPEX savings.
A: Mix resets by channel, OPEX savings not in current run rate